Cargando…

Maintenance therapy in multiple myeloma

Detalles Bibliográficos
Autor principal:	Harousseau, Jean-Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222249/ http://dx.doi.org/10.4081/hr.2009.e12

Ejemplares similares

CAR-T cell therapy in myeloma: hopes and hurdles
por: Harousseau, Jean Luc
Publicado: (2023)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

The role of maintenance therapy in multiple myeloma
por: Lipe, B, et al.
Publicado: (2016)

Future Directions in Maintenance Therapy in Multiple Myeloma
por: Holstein, Sarah A., et al.
Publicado: (2021)

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Posttransplant maintenance therapy in multiple myeloma: the changing landscape
por: Sengsayadeth, S, et al.
Publicado: (2017)

Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
por: Nunnelee, Jordan, et al.
Publicado: (2022)

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma
por: Sagar, FNU, et al.
Publicado: (2018)

Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
por: Lee, Ho Sup, et al.
Publicado: (2016)

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
por: Buda, Gabriele, et al.
Publicado: (2010)

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
por: Zhang, Shijia, et al.
Publicado: (2020)

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
por: Luoma, Sini, et al.
Publicado: (2023)

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
por: Stroh, Jacob, et al.
Publicado: (2022)

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
por: Bradwell, A, et al.
Publicado: (2013)

Lenalidomide in the Treatment of Young Patients with Multiple Myeloma: From Induction to Consolidation/Maintenance Therapy
por: Lupo, Barbara, et al.
Publicado: (2012)

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Post-Transplant Maintenance Treatment Options in Multiple Myeloma
por: Karam, Dhauna, et al.
Publicado: (2021)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.
por: Bell, J. B., et al.
Publicado: (1994)

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
por: Belch, A., et al.
Publicado: (1988)

Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
por: Nakaya, Aya, et al.
Publicado: (2021)

Pain as a risk factor of depression and anxiety symptoms with multiple myeloma during maintenance therapy
por: Shi, Hui, et al.
Publicado: (2022)

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010)

Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide maintenance therapy: a case report
por: Cao, Xueqin, et al.
Publicado: (2022)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy
por: Jackson, Graham, et al.
Publicado: (2019)

Immune Recovery after Cyclophosphamide Treatment in Multiple Myeloma: Implication for Maintenance Immunotherapy
por: Sharabi, Amir, et al.
Publicado: (2011)

Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials
por: Li, Jie-Li, et al.
Publicado: (2018)

PB2162: EVALUATION OF IMMUNE RECONSTITUTION IN MULTIPLE MYELOMA PATIENTS ON MAINTENANCE THERAPY WITH LENALIDOMIDE - THE ROLE OF HEAVYLITE CHAINS
por: Miranda, Mariana, et al.
Publicado: (2023)

New therapies in multiple myeloma
por: Merchionne, F., et al.
Publicado: (2007)

Diagnosis and therapy of multiple myeloma
por: Palumbo, Antonio, et al.
Publicado: (2013)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Targeted Therapies for Multiple Myeloma
por: Leow, Christopher Chang-Yew, et al.
Publicado: (2021)

Targeted therapy of multiple myeloma
por: Zhou, Shan, et al.
Publicado: (2021)

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
por: Pulte, Elizabeth Dianne, et al.
Publicado: (2018)

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
por: Duane, C., et al.
Publicado: (2022)

PB2033: INFLUENCE OF INDUCTION THERAPY WITH LENALIDOMIDE ON MAINTENANCE THERAPY AND PROGNOSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Sun, Q., et al.
Publicado: (2022)

Antibody-Based Therapies in Multiple Myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2011)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6abs9r2jvfj4u33a47meff1cnf